1	Temporal trends of dengue seroprevalence among children in coastal Kenya, 1998–2018: a
2	longitudinal cohort study
3	Henry K. Karanja ¹ , Benedict Orindi ¹ , John N. Gitonga ¹ , Daisy Mugo ¹ , Kennedy Mwai ¹ , Doris K.
4	Nyamwaya ¹ , Donwilliams Omuoyo ¹ , Barnes S. Kitsao ¹ , Jennifer N. Musyoki ¹ , Julianna Wambua ¹ ,
5	Edward Otieno ^{1,2} , Lynette Isabella Ochola-Oyier ¹ , Philip Bejon ^{1,2} , George M. Warimwe ^{1,2}
6	¹ Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Kenya;
7	² Nuffield Department of Medicine, University of Oxford, UK

8

9 Abstract

10 Serosurveys suggest widespread dengue virus (DENV) transmission in Africa but there is limited information on the temporal patterns of exposure. Here, we estimated the prevalence and incidence 11 of DENV infections in coastal Kenya over a 20-year period (1998-2018). Sera (n=8038) obtained 12 annually from a longitudinal cohort of 1847 children aged 15 years and below were screened for anti-13 DENV IgG antibodies. Anti-DENV IgG seroprevalence increased with age and peaked during 14 15 outbreak years. Among 1354 children who were seronegative at recruitment, we observed an overall incidence (seroconversion) rate of 129.5 (95% CI 118.7-141.4) DENV infections per 1000 person-16 years. The highest incidence was observed in 2013 at 520 infections per 1000 person-years (95% CI 17 18 443.6–610.2) coinciding with a large DENV outbreak in coastal Kenya. Our data suggest long-term DENV exposure among children in coastal Kenya highlighting an urgent need for clinical 19 20 surveillance to determine the associated health burden in this setting.

21

22 Introduction

Dengue virus (DENV) is the most widespread arbovirus globally, causing over 300 million infections
 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
 every year (1). This positive-stranded RNA virus belongs to the genus flavivirus and is composed of

a genome, approximately 11kb in size, that exists in four distinct serotypes (DENV-1 to DENV-4) 25 that can be further classified into multiple genotypes (2). Infection results in long-lived protection 26 against the infecting DENV serotype but only short-lived cross-protection against heterologous 27 28 serotypes (3). DENV is primarily transmitted by Aedes aegypti mosquitoes whose wide geographic distribution accounts for the high global burden of the disease (4, 5). Most DENV infections are 29 asymptomatic, but an estimated 100 million clinical cases occur every year with manifestations 30 ranging from a mild self-limiting febrile illness to life-threatening symptoms such as hemorrhagic 31 fever and shock syndrome (2). Licensed dengue vaccines are now available for use in settings where 32 33 the disease in endemic (6, 7). Knowledge of the burden and geographic distribution of DENV infections is essential for efficient deployment and use of dengue vaccines and other disease control 34 interventions. 35

The burden of DENV infections in Africa is poorly defined with most literature focusing on disease 36 outbreaks in Asia and the Americas (8). A modelling study suggests that Africa accounts for more 37 38 than 16% of the global burden of DENV infections annually (1). The limited seroprevalence and outbreak report data available support widespread viral transmission on the continent (9), but there 39 are insufficient data on the age-specific risk of DENV exposure to inform local prioritization for 40 41 clinical surveillance and public health response. In Kenya, dengue outbreaks have been reported since 1982 with wide geographic risk of exposure (10-12). DENV-2 was implicated in the initial 1982 42 outbreak in coastal Kenya (10), and though other serotypes are in circulation (11-13), DENV-2 is 43 44 most frequently associated with outbreaks in Kenya and other settings in Africa (9, 14). For instance, recent clinical surveillance in western and coastal Kenya during 2014 to 2017 identified a high 45 prevalence of DENV viraemia among children with undifferentiated fever (42% of 862 patients); 46 47 while viral genomes from all 4 DENV serotypes were detected, DENV-2 accounted for more than half of the sequenced genomes (13). Together, these data suggest high levels of DENV exposure in 48 49 Kenya, but the extent to which exposure has varied over time remains unknown.

Here, we use a biobank to investigate the temporal trends of DENV exposure in coastal Kenya where
the bulk of DENV outbreaks in Kenya have been reported. We used immunoglobin G (IgG) serology
to estimate the age-specific prevalence of anti-DENV IgG antibody among children aged between 6
months and 15 years over a 20-year period, that is, 1998 to 2018.

54

55 Materials and methods

56 Study population

This study was nested within an ongoing longitudinal cohort study at the Kenya Medical Research 57 Institute (KEMRI)-Wellcome Trust Research Programme in Kilifi, coastal Kenya conducted since 58 59 1998 to date with the main aim of describing malaria incidence and transmission in this area (15, 16). Briefly, children resident in Junju and Ngerenya sub-locations within the Kilifi Health and 60 Demographic Surveillance System (KHDSS) (17) are recruited at birth and remain in the cohort until 61 62 the age of 15 years. The malaria surveillance has been running in Ngerenya since 1998 and in Junju since 2005. Every year, a cross-sectional survey is conducted and includes blood sampling of cohort 63 participants and collection of demographic data. Sera (and linked demographic data) collected during 64 these annual cross-sectional surveys were available at the KEMRI-Wellcome Trust Research 65 Programme biobank, allowing an assessment of DENV seroprevalence over time. Ethical approval 66 was provided by the KEMRI Scientific and Ethics Review Unit (KEMRI SERU # 3296, #1131). 67

68 Estimation of DENV exposure by serology

We measured anti-DENV IgG antibodies by enzyme-linked immunosorbent assay (ELISA) against a local DENV-2 isolate obtained from a patient in the same geographic setting (*18*). DENV-2 was selected for this assay owing to its frequent circulation in Kenya and ready availability of DENV-2 virus in our lab (*13, 19, 20*). Briefly, 96 wells Maxisorp flat-bottomed plates were coated with 50µL of ~1x10³ TCID₅₀ whole DENV-2 virus lysate per well and incubated for 1 hour at room temperature (RT), fixed with 4% paraformaldehyde for 30 minutes at RT and blocked with BlockerTM Casein in

75 Phosphate Buffered Saline (PBS) (ThermoScientific, cat. # 37528). Serum samples were diluted 1:500 in Blocker[™] Casein and added to the DENV-coated plates and incubated for 2 hours at 37°C. 76 The plates were washed 3 times with wash buffer (0.1% Tween20 in PBS), after which 1:10000 77 78 dilution of Peroxidase Labelled Goat Anti-Human IgG (Cat. # 074-1002, KPL) in wash buffer was added to the plates and incubated for one hour. After another series of washes, the plates were 79 developed by adding 100µL/well of reconstituted o-phenylenediamine dihydrochloride (Sigma, cat. 80 # 8287) for 15–20 minutes and the reaction stopped by adding 100µl/well of 2NH₂SO₄. Colour 81 reaction was measured at 492nm by the Tecan Infinite® 200 PRO. Each plate included serial dilutions 82 83 of a pooled sera sample from six Kenyan adults with high virus neutralising antibody titres against DENV-2 from which a standard curve was generated and used to extrapolate IgG responses 84 (expressed as ELISA units) for each test sample. To define a seropositivity cut-off we used the whole 85 virus IgG ELISA to test sera from 108 adults with corresponding focus reduction neutralisation test 86 (FRNT₉₀) data (18) and determined the sensitivity and specificity of the IgG ELISA in detecting 87 DENV-2 FRNT₉₀ positive sera. An IgG ELISA unit cut-off \geq 250 had a specificity of 91.1% and 88 sensitivity of 92.1% in identifying individuals with DENV-2 neutralising antibodies as measured by 89 90 FRNT₉₀ assay and was therefore used for the analysis presented herein. Because IgG ELISA cannot 91 reliably distinguish DENV serotype-specific responses (2), which requires use of the highly specific virus neutralisation assays, we describe the IgG immune responses as anti-DENV rather than anti-92 DENV-2. 93

94 Statistical analysis

First, we estimated DENV seroprevalence, together with the associated 95% Agresti-Coull confidence interval by sex, age, location of residence (Junju or Ngerenya) and year of sampling. Next, to assess whether the seroprevalence varied with sex, age, location and year we fitted a mixed-effects logistic regression model, with child as a random effect. Age entered the model as a linear spline function with a single knot at 10 years (*21*), such that we estimated the linear effect of age up to the age of 10 years then the linear effect of age after 10 years. The covariates were tested using the

101 likelihood ratio (LR) test. Finally, we estimated incidence rates (IR) of DENV infection (defined as IgG seropositivity in the whole virus ELISA) among children and compared across variables using 102 Poisson regression, with the logarithm of person-years as offset. This analysis only included children 103 104 who were initially DENV seronegative at recruitment, and children were censored after their first DENV infection (that is, when they turned IgG seropositive). We report incidence rates per 1000 105 person-years. Data were analysed using Stata version 17.0 (StataCorp, College Station, TX) and 106 graphs generated using GraphPad Prism version 9.5.1 (GraphPad Software, San Diego, California 107 USA). All tests were performed at 0.05 significance level. 108

109

110 Results

A total of 8038 serum samples obtained from 1847 children at annual cross-sectional surveys between 31st August 1998 and 10th April 2018 were available in the KEMRI-Wellcome Trust Research Programme biobank. The median number of annual cross-sectional surveys (or years of follow-up) for the 1847 children was 2 (range 1–14), contributing to a total of 7394.2 years of follow-up over the 20-year period. The median age of the children over the entire follow-up period was 7.1 years (interquartile range 4.1–10.3). Of the 8038 serum samples 3965 (49.3%) came from children resident in Junju and 4073 (50.7%) were from residents of Ngerenya (Table 1).

Overall, 2295 (28.6%, 95% CI 27.6–29.5%) of the 8038 samples were seropositive for DENV IgG 118 antibodies. However, DENV seroprevalence markedly increased with age from a low of 2.2% 119 120 among children aged below 1 year to a high of 40% among those aged 9 and 10 years (Odds ratio (OR) 1.46, 95% CI 1.40–1.52; p<0.001), after which the seroprevalence remained the same (OR 121 122 0.97, 95% CI 0.92-1.03) (Figure 1C and Table 1). DENV seroprevalence varied substantially over the years (LR test p<0.0001) with seroprevalence as high as 60% observed in 1998 and 2013, to a 123 low of approximately 12% in 2017 (Figure 1A) but did not vary significantly by sex (p=0.438) and 124 location (p=0.834) (Table 1). 125

126 During the 20-year period, we observed 503 new DENV infections (i.e., seroconversion among 1354 participants who were seronegative at recruitment), giving an overall incidence rate of 129.2 (95% 127 CI 118.4–141.0) DENV infections per 1000 person-years. The incidence of seroconversion did not 128 129 vary by sex (incidence rate ratio (IRR) 1.02, 95% CI 0.85–1.21; p=0.841) and geographical location of residence (p=0.365), but it linearly increased with age at the rate of 5% per one year increase in 130 age up to around the age of 9–10 years (IRR 1.05, 95% CI 1.01–1.10; p=0.019) (Table 1 and Figure 131 1D). The highest incidence of seroconversion was observed in 2013 at 520 cases per 1000 person-132 years (95% CI 443.6-610.2), followed by 2008 at 182.3 cases per 1000 person-years (95% CI 130.9-133 134 253.9) and 2011 at 174.8 cases per 1000 person-years (95% CI 137.8-221.7) (Figure 1B; LR test p<0.001). 135

136

137 **DISCUSSION**

There is limited surveillance for DENV in Africa beyond sporadic reporting of outbreaks (22). The true burden of DENV infections therefore remains unknown with modelling studies suggesting a burden in Africa that is at least as high as that in Latin America (1). Most of the previous serological assessments of DENV exposure in Africa have tended to be cross-sectional in nature, providing information on the geographical extent of DENV transmission but limited information on the temporal dynamics of viral exposure (14). Our data provide a two-decade assessment of DENV infections in coastal Kenya.

We confirm high levels of DENV exposure in coastal Kenya, in keeping with previous serological studies and outbreak reports (*11, 12, 18*). DENV seropositivity showed a positive relationship with age suggesting ongoing endemic transmission in this setting. Seropositivity peaked in 1998–2000 and 2013, coinciding with periods when DENV cases were reported in neighbouring countries (Tanzania and Uganda in 1999–2000 (*14*)) and with one of the largest DENV outbreaks in coastal Kenya reported in 2013 (*23*). During the 2013 outbreak, DENV cases were predominantly reported in

Mombasa (23). However, the very high incidence of DENV seroconversion observed in Kilifi, approximately 50km north of Mombasa, during this period suggests that the outbreak was more widespread along the Kenyan coast than previously thought (11). We also detected high incidence of DENV seroconversion during 2008 and 2011, coinciding with a confirmed DENV outbreak in northern Kenya and neighbouring Somalia in 2011 (24), and a possible undetected outbreak in 2008 in coastal Kenya. These incidence data support the utility of serology in inferring exposure to DENV infections.

DENV-2 has been implicated in most outbreaks and case reports in Africa, but other DENV serotypes 158 159 are increasingly being detected during outbreaks, including importations from Asia (9, 14). Increasing circulation of multiple DENV serotypes is of public health concern due to the potential for severe 160 disease associated with serial infection with heterologous DENV serotypes (25). Two types of 161 162 immune responses are elicited by infection: a long-lived protective antibody response against the infecting DENV serotype and a short-lived cross-reactive response against other (heterologous) 163 164 DENV serotypes (2, 3). During subsequent infection(s) with a heterologous DENV serotype, these cross-reactive weaker antibody responses are unable to neutralize virus infection but instead facilitate 165 Fc-mediated virus entry into host cells (e.g. monocytes) allowing the virus to thrive whilst evading 166 167 other host anti-viral defenses, resulting in enhanced pathology that underlies severity disease (2, 25). Our assay could not distinguish DENV serotype-specific responses. However, the high levels of 168 DENV exposure observed indicate an urgent need for long-term systematic clinical and 169 170 immunological surveillance to characterise DENV infections in this setting, the associated symptoms and outcomes, and the predisposing risk factors. All four DENV serotypes have been associated with 171 febrile illness in children in Kenya (13), but interestingly, the current WHO clinical diagnostic criteria 172 for dengue performed poorly in this setting with no severe complications observed (26). This further 173 highlights a need for development of clinical algorithms that can identify patients with DENV 174 175 infection in East Africa, both for clinical diagnosis and for use in evaluation of disease control interventions. 176

177 This study had limitations. First, we used whole DENV-2 virus for the detection of circulating IgG antibodies and while assay performance was good in comparison to virus neutralising responses, the 178 assay cannot distinguish DENV serotype-specific responses and it is likely there were cross-reactive 179 responses against other DENV serotypes and related flaviviruses (e.g., Zika virus). The relative 180 contribution of the four DENV serotypes to the observed exposure levels could therefore not be 181 determined. Nevertheless, we could detect incident cases during periods when DENV outbreaks were 182 reported in Kenya (23), and our previous work suggests limited circulation of Zika virus in the study 183 location (18). Second, this study provides an unprecedented 20-year longitudinal assessment of 184 185 DENV exposure in coastal Kenya. While this has allowed a long-term view of exposure trends, the limited geographical focus precludes generalisation to other settings in the country and the region. 186 However, previous dengue outbreaks have tended to involve multiple countries in East Africa, and 187 188 the shared ecology supportive of the Aedes spp and other mosquito vectors suggests DENV infections (as with other arboviruses) may be widespread in the region (8, 27, 28). Finally, we did not monitor 189 clinical illness and therefore could not determine what fraction of the observed exposures had 190 experienced symptomatic infections. With licensed dengue vaccines now available (6, 7), an 191 assessment of the disease burden in Kenya and other African countries is urgently needed to inform 192 193 decisions on vaccine deployment and use.

194

195 Acknowledgements

This work was funded by Wellcome Trust grant (grant number 203077_Z_16_Z to PB) and an Oak
Foundation fellowship to GMW. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.

199

200 **References**

1. S. Bhatt *et al.*, The global distribution and burden of dengue. *Nature* **496**, 504-507 (2013).

- 202 2. A. Wilder-Smith, E. E. Ooi, O. Horstick, B. Wills, Dengue. *Lancet* **393**, 350-363 (2019).
- 203 3. W. M. Wahala, A. M. Silva, The human antibody response to dengue virus infection.
- 204 *Viruses* **3**, 2374-2395 (2011).
- O. J. Brady, S. I. Hay, The Global Expansion of Dengue: How Aedes aegypti Mosquitoes
 Enabled the First Pandemic Arbovirus. *Annu Rev Entomol* 65, 191-208 (2020).
- M. U. Kraemer *et al.*, The global distribution of the arbovirus vectors Aedes aegypti and Ae.
 albopictus. *Elife* 4, e08347 (2015).
- S. Biswal *et al.*, Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and
 Adolescents. *N Engl J Med* 381, 2009-2019 (2019).
- 211 7. M. R. Capeding *et al.*, Clinical efficacy and safety of a novel tetravalent dengue vaccine in
- healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
- 213 *Lancet* **384**, 1358-1365 (2014).
- E. M. Gainor, E. Harris, A. D. LaBeaud, Uncovering the Burden of Dengue in Africa:
 Considerations on Magnitude, Misdiagnosis, and Ancestry. *Viruses* 14, (2022).
- 9. G. O. Mwanyika *et al.*, Dengue Virus Infection and Associated Risk Factors in Africa: A
- 217 Systematic Review and Meta-Analysis. *Viruses* **13**, (2021).
- 218 10. B. K. Johnson, S. Musoke, D. Ocheng, A. Gichogo, P. H. Rees, Dengue-2 virus in Kenya.
 219 *Lancet* 2, 208-209 (1982).
- L. Konongoi *et al.*, Detection of dengue virus serotypes 1, 2 and 3 in selected regions of
 Kenya: 2011-2014. *Virol J* 13, 182 (2016).
- E. M. Muthanje *et al.*, March 2019 dengue fever outbreak at the Kenyan south coast
 involving dengue virus serotype 3, genotypes III and V. *PLOS Glob Public Health* 2,
 e0000122 (2022).
- M. M. Shah *et al.*, High Dengue Burden and Circulation of 4 Virus Serotypes among
 Children with Undifferentiated Fever, Kenya, 2014-2017. *Emerg Infect Dis* 26, 2638-2650 (2020).

- A. Amarasinghe, J. N. Kuritsk, G. W. Letson, H. S. Margolis, Dengue virus infection in
 Africa. *Emerg Infect Dis* 17, 1349-1354 (2011).
- 230 15. T. W. Mwangi, A. Ross, R. W. Snow, K. Marsh, Case definitions of clinical malaria under
- different transmission conditions in Kilifi District, Kenya. J Infect Dis **191**, 1932-1939
- 232 (2005).
- 233 16. A. Olotu *et al.*, Defining clinical malaria: the specificity and incidence of endpoints from
- active and passive surveillance of children in rural Kenya. *PLoS One* **5**, e15569 (2010).
- I. A. Scott *et al.*, Profile: The Kilifi Health and Demographic Surveillance System
 (KHDSS). *Int J Epidemiol* 41, 650-657 (2012).
- 18. H. C. Barsosio *et al.*, Congenital microcephaly unrelated to flavivirus exposure in coastal
- 238 Kenya. *Wellcome Open Res* **4**, 179 (2019).
- 239 19. E. Kamau *et al.*, Complete Genome Sequences of Dengue Virus Type 2 Strains from Kilifi,
 240 Kenya. *Microbiol Resour Announc* 8, (2019).
- 241 20. M. M. Masika *et al.*, Detection of dengue virus type 2 of Indian origin in acute febrile
 242 patients in rural Kenya. *PLoS Negl Trop Dis* 14, e0008099 (2020).
- 243 21. N. A. Schuster, J. J. M. Rijnhart, J. W. R. Twisk, M. W. Heymans, Modeling non-linear
 244 relationships in epidemiological data: The application and interpretation of spline models.
 245 *Front. Epidemiol.*, (2022).
- 246 22. T. Jaenisch *et al.*, Dengue expansion in Africa-not recognized or not happening? *Emerg*247 *Infect Dis* 20, (2014).
- 248 23. E. M. Ellis *et al.*, A household serosurvey to estimate the magnitude of a dengue outbreak in
 249 Mombasa, Kenya, 2013. *PLoS Negl Trop Dis* 9, e0003733 (2015).
- 250 24. M. Obonyo, A. Fidhow, V. Ofula, Investigation of laboratory confirmed Dengue outbreak in
 251 North-eastern Kenya, 2011. *PLoS One* 13, e0198556 (2018).
- 252 25. S. B. Halstead, Neutralization and antibody-dependent enhancement of dengue viruses. *Adv* 253 *Virus Res* 60, 421-467 (2003).

- 254 26. A. Khan *et al.*, Majority of pediatric dengue virus infections in Kenya do not meet 2009
- 255 WHO criteria for dengue diagnosis. *PLOS Glob Public Health* **2**, e0000175 (2022).
- 256 27. A. A. Bettis *et al.*, The global epidemiology of chikungunya from 1999 to 2020: A
- 257 systematic literature review to inform the development and introduction of vaccines. *PLoS*
- 258 *Negl Trop Dis* **16**, e0010069 (2022).
- 259 28. K. N. Gerken *et al.*, Paving the way for human vaccination against Rift Valley fever virus:
- A systematic literature review of RVFV epidemiology from 1999 to 2021. *PLoS Negl Trop*
- 261 *Dis* **16**, e0009852 (2022).

262

				Seroprevalence				Incidence			
	Number of	Number	Samples	% positive	Adjusted odds	P-value	Person	Cases	Incidence rate/1000	Incidence rate ratio	P-value
	children	of	positive	(95% CI)	ratio (95% CI)		years*		person-years (95% CI)	(95% CI)	
		samples									
Overall	1847	8038	2295	28.6 (27.6–29.5)			3893.2	503	129.2 (118.4–141.0)		
Sex											
Female	900	3849	1089	28.3 (26.9–29.7)	Reference		1875.2	239	127.5 (112.3–144.7)	Reference	
Male	947	4189	1206	28.8 (27.4–30.2)	1.10 (0.87–1.38)	0.438	2018.0	264	130.8 (116.0–147.6)	1.02 (0.85–1.21)	0.841
Age in years**											
Age spline 1					1.46 (1.40–1.52)	< 0.001				1.05 (1.01–1.10)	0.019
Age spline 2					0.97 (0.92–1.03)	0.310				0.98 (0.90–1.106)	0.564
Location											
Junju	907	3965	1019	25.7 (24.4–27.1)	Reference		1680.9	249	148.1 (130.8–167.7)	Reference	
Ngerenya	940	4073	1276	31.3 (29.9–32.8)	0.97 (0.73–1.29)	0.834	2212.2	254	114.8 (101.5–129.8)	0.91 (0.74–1.12)	0.365

263 Table 1. Prevalence and incidence rates of DENV infection among children in Kilifi by sex, age and location

264

265 *Person-years contributed by the 1847 children up to the point of their first DENV infection detection, beyond which children were censored.

**Non-linear age effect was modelled using a 1-knot linear spline. Age spline 1 represent the continuous age measurements in the range 0.5 to 10; age spline 2 represent the

continuous age measurements in the range 10–15 years. Age splines 1 and 2 estimate the linear effect of age in those two age ranges.

Figure 1. Prevalence and incidence of DENV IgG antibodies by year of sampling and age of 268

the children 269



270

Presented in (A) are the percentages of children with anti-DENV IgG antibodies in each annual cross-271 sectional survey during the study period. In (B) the incidence of anti-DENV IgG seroconversion 272 273 among children who were seronegative for DENV at recruitment is shown over time. (C) presents the percentages of children with anti-DENV IgG antibodies from 1998–2018 by 1-year age bands. (D) 274 presents the incidence of anti-DENV IgG seroconversion among children who were seronegative for 275 DENV at recruitment by 1-year age bands. An incidence estimate could not be made for the year 276 1998 and for children aged below 1 year as participants did not have a positive time at risk. The bold 277 arrows indicate when dengue outbreaks occurred in Kenya (solid) and in neighbouring countries 278 (dashed). 279

280

281